艾迪注射液加同步放化疗治疗局部晚期非小细胞肺癌临床探究.docVIP

艾迪注射液加同步放化疗治疗局部晚期非小细胞肺癌临床探究 　 作者：周祖金 刘少兵 卢丽杰 【摘要】 目的 观察艾迪注射液联合同步放化疗对局部晚期非小细胞肺癌的治疗效果。方法 50例局部晚期非小细胞肺癌患者，随机分为两组，综合组25例：采用盖诺+顺铂方案同步放化疗，放疗予常规分割，2Gy/f，总量56～60Gy，同时加用艾迪50ml静脉滴注,15d为1个疗程,共2个疗程。对照组25例，采用盖诺+顺铂方案同步放化疗。2个疗程后评价疗效，通过KPS评分、体重变化，观察生存质量改善情况。结果 两组完全缓解率分别为24.0％（6/25）和12.0％（3/25）（Pgt;0.05）；有效率分别为76.0%（19/25）和68.0％（17/25）（Pgt;0.05）；综合组Ⅲ级以上骨髓抑制发生率为40.0％（10/25），而对照组为68.0%（17/25）（Plt;0.05）；综合组Ⅲ级以上消化道不良反应发生率为8.0％（2/25），对照组为36.0％（9/25）（Plt;0.05）；综合组无Ⅲ级以上放射性肺炎发生（0/25），而对照组为4.0%（1/25）（Pgt;0.05）；综合组Ⅲ级以上放射性食管炎发生率16.0%（4/25），对照组为44.0%（11/25）（Plt;0.05）；综合组治疗前后KPS评分及体重评分明显高于对照组（Plt;0.05）。结论 艾迪联合同步放化疗可以减轻放化疗引起的胃肠道反应，减少Ⅲ级以上骨髓抑制和Ⅲ级以上放射性食管炎的发生，使患者的生存质量得到改善，并有可能进一步提高局部晚期非小细胞肺癌同步放化疗的疗效。 【关键词】 艾迪注射液 同步放化疗 非小细胞肺癌 【Abstract】 Objective To evaluate the clinical toxicity and efficacy of Aidi in jection combined with concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer. Methods Fifty patients with locally advanced non-small cell lung cancer were randomized into two groups. The combination group received chemotherapy of NVB+DDP regimen, radiotherapy was given with conventional fraction in 2Gy per fraction and five fractions per week. The total doses were 56～60 Gy. Combined with Aidi injection for consecutive fifteen days for two courses, and the control group was chemoradiotherapy only. Toxicityes and effects wer evaluated according to the criteria of WHO. Results The CR in combination group and control group were 24.0%（6/25）and 12.0%（3/25）,respectively(Pgt;0.05).Response rate of combination group was 76.0%(19/25) and 68.0%(17/25) in control group(Pgt;0.05). Grade 3-4 leukocytopenia, grade 3-4 digestive system and grade 3-4 digestive system and grade 3-4 radiation esophatitis in combination group and control group were 40.0%(10/25),8.0%(2/25),16.0%(4/25) and 68.0%(17/25),36.0%(9/25), 44.0%(11/25),respectively(Plt;0.05). KPS and bodyweight score significantly increased in combination group after the combined treatment(Plt;0.05). Conclusion Aidi injection